Placebo News and Research

RSS

UC Davis Health joins with Novavax to test a new experimental coronavirus vaccine

Despite the encouraging news of potentially successful COVID-19 vaccine trials, there is not yet an FDA-approved vaccine available. Research into other effective coronavirus vaccines continues, including at UC Davis Health.

8 Dec 2020

Combination of venetoclax and standard therapies shows promise in high-risk myeloid blood cancers

The novel oral drug venetoclax can be safely added to standard therapies for some high-risk myeloid blood cancers and in early studies the combination shows promise of improved outcomes, say scientists from Dana-Farber Cancer Institute.

7 Dec 2020

Secukinumab for treatment of plaque psoriasis in children: Added benefit not proven

The monoclonal antibody secukinumab is approved for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of six years who are candidates for systemic therapy.

5 Dec 2020

β-AR agonist therapy may prevent metastasis in oral squamous cell carcinoma

Affecting almost 600,000 people worldwide every year, and with only a 50% survival rate, oral squamous cell carcinoma (OSCC) is one of the more common and deadly forms of cancer.

4 Dec 2020

New antiviral drug completely suppresses SARS-CoV-2 transmission within 24 hours

Treatment of SARS-CoV-2 infection with a new antiviral drug, MK-4482/EIDD-2801 or Molnupiravir, completely suppresses virus transmission within 24 hours, researchers in the Institute for Biomedical Sciences at Georgia State University have discovered.

3 Dec 2020

Medically active component of cannabis does not impact driving ability, study shows

A landmark study on how cannabis affects driving ability has shown that cannabidiol (CBD), a cannabis component now widely used for medical purposes, does not impair driving, while moderate amounts of the main intoxicating component tetrahydrocannabinol (THC) produce mild driving impairment lasting up to four hours.

1 Dec 2020

KU Leuven vaccine candidate works against yellow fever and SARS-CoV-2 infection

Virologists at the Rega Institute at KU Leuven (Belgium) have developed a vaccine candidate against Covid-19 based on the yellow fever vaccine, which as a result also works against yellow fever. Results published today in Nature show that the vaccine protects hamsters from infection with the SARS-CoV-2 coronavirus after a single dose.

1 Dec 2020

Marinomed plans a clinical trial with Carragelose nasal spray as COVID-19 prophylaxis

Marinomed Biotech AG, a globally operating biopharmaceutical company, is pleased to announce today that the Swansea University Medical School plans a clinical trial with Iota-/kappa-carrageenan nasal spray as a COVID-19 Prophylaxis for Healthcare Professionals (ICE-COVID).

30 Nov 2020

Rutgers leading a clinical trial assessing combination treatment for coronavirus

Rutgers is leading a clinical trial assessing the combination of nitazoxanide, ribavirin and hydroxychloroquine to treat people 21 or older who are infected with SARS-CoV-2 and are asymptomatic or mildly symptomatic.

30 Nov 2020

Adding exercise to genetic treatment reverses fatigue in mice with common myotonic dystrophy

Adding exercise to a genetic treatment for myotonic dystrophy type 1 (DM1) was more effective at reversing fatigue than administering the treatment alone in a study using a mouse model of the disease.

30 Nov 2020

New drug treatment could soon benefit people with rheumatoid arthritis

People with Rheumatoid Arthritis (RA) could soon benefit from a new drug treatment that not only suppresses inflammation but also significantly reduces patient reported pain scores. Otilimab is a monoclonal antibody, biologic drug, which targets and suppresses the inflammatory cytokine GM-CSF.

25 Nov 2020

Getting adequate sleep may help teens with migraines

Research indicates that starting school later in the morning yields health and academic benefits for high schoolers, whose natural body clock tends toward late-to-bed, late-to-rise habits.

25 Nov 2020

Convalescent plasma therapy ineffective in treating severe COVID-19, study finds

A recent study based at a hospital in Buenos Aires, Argentina, found that convalescent plasma therapy for patients with severe COVID-19, and COVID-19-related pneumonia, was largely ineffective.

25 Nov 2020

Widely used antibiotic shows promise for fighting against Zika infections

In 2015, hundreds of children were born with brain deformities resulting from a global outbreak of Zika virus infections.

24 Nov 2020

Early high-titer convalescent plasma prevents 75% of severe COVID-19 in elderly

A promising new clinical study published on the preprint server medRxiv reports that if convalescent plasma with a high titer of antibodies is given early in the course of COVID-19 in elderly patients, the risk of severe illness is reduced by 73%.

24 Nov 2020

Marinomed to initiate clinical trial with Carragelose for preventing COVID19 in frontline healthcare staff

Marinomed Biotech AG, a globally operating biopharmaceutical company, announced today plans to initiate a Phase IV clinical trial with Carragelose (iota-carrageenan).

23 Nov 2020

FDA expands approved indication for influenza treatment to include post-exposure prevention

Today, the U.S. Food and Drug Administration expanded the approved indication for Xofluza (baloxavir marboxil) to include post-exposure prevention of influenza (flu) for patients 12 years of age and older after contact with an individual who has the flu.

23 Nov 2020

FDA schedules meeting to discuss emergency use authorization of COVID-19 vaccine from Pfizer

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for casirivimab and imdevimab to be administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older weighing at least 40 kilograms [about 88 pounds]) with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progressing to severe COVID-19.

23 Nov 2020

Sinovac Biotech's COVID-19 vaccine candidate triggers immune response

Now, Sinovac Biotech's candidate vaccine, CoronaVac, has been found to induce an immune response in healthy adults aged 18–59 years, 28 days post-vaccination. However, the level of antibodies generated was lower than in people who had recovered from the illness.

19 Nov 2020

Texas Heart Institute to participate in a study to treat ARDS in hospitalized COVID-19 patients

Texas Heart Institute has been selected as one of up to 60 sites in the world to participate in an international investigative study seeking to aid COVID-19 patients who develop acute respiratory distress syndrome (ARDS).

19 Nov 2020

Placebo News and Research

UC Davis Health joins with Novavax to test a new experimental coronavirus vaccine

Combination of venetoclax and standard therapies shows promise in high-risk myeloid blood cancers

Secukinumab for treatment of plaque psoriasis in children: Added benefit not proven

β-AR agonist therapy may prevent metastasis in oral squamous cell carcinoma

New antiviral drug completely suppresses SARS-CoV-2 transmission within 24 hours

Medically active component of cannabis does not impact driving ability, study shows

KU Leuven vaccine candidate works against yellow fever and SARS-CoV-2 infection

Marinomed plans a clinical trial with Carragelose nasal spray as COVID-19 prophylaxis

Rutgers leading a clinical trial assessing combination treatment for coronavirus

Adding exercise to genetic treatment reverses fatigue in mice with common myotonic dystrophy

New drug treatment could soon benefit people with rheumatoid arthritis

Getting adequate sleep may help teens with migraines

Convalescent plasma therapy ineffective in treating severe COVID-19, study finds

Widely used antibiotic shows promise for fighting against Zika infections

Early high-titer convalescent plasma prevents 75% of severe COVID-19 in elderly

Marinomed to initiate clinical trial with Carragelose for preventing COVID19 in frontline healthcare staff

FDA expands approved indication for influenza treatment to include post-exposure prevention

FDA schedules meeting to discuss emergency use authorization of COVID-19 vaccine from Pfizer

Sinovac Biotech's COVID-19 vaccine candidate triggers immune response

Texas Heart Institute to participate in a study to treat ARDS in hospitalized COVID-19 patients

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News